Search

Your search keyword '"Ishigo S"' showing total 6 results
Start Over Author "Ishigo S" Topic gram-negative bacteria
6 results on '"Ishigo S"'

1. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].

Author

Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Shinagawa M, Yasujima M, Suwabe A, Kuroda M, Kaku M, Kitagawa M, Kanemitsu K, Imafuku Y, Murakami M, Yomodu S, Taniguchi N, Yamada T, Nomura F, Kanno H, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Horikawa Y, Maekawa M, Nagura O, Yagi T, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kawano S, Kinoshita S, Taminato T, Negayama K, Murase M, Miyamoto H, Kusano N, Nose M, Yokozaki M, Itaha H, Matsunaga A, Yoshimura H, Kohno S, Yanagihara K, Matsuda J, Saikawa T, and Hiramatsu K

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Dosage Forms, Drug Resistance, Bacterial, Humans, Infant, Infant, Newborn, Japan, Meropenem, Middle Aged, Respiratory System microbiology, Time Factors, Urine microbiology, Young Adult, Anti-Bacterial Agents pharmacology, Bacteria, Anaerobic drug effects, Bacteria, Anaerobic isolation & purification, Bacterial Infections microbiology, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Positive Bacteria drug effects, Gram-Positive Bacteria isolation & purification, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; (1) MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multidrug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). (2) MEPM maintained potent and stable antibacterial activity against Pseudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. (3) The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-beta-lactamase strains was 2.0% (6 strains) in P. aeruginosa. (4) Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

Published
2011

2. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].

Author

Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, Kasai T, Suwabe A, Yamahata K, Kaku M, Kanemitsu K, Imafuku Y, Nishiyama K, Murakami M, Yomoda S, Taniguchi N, Yamada T, Nomura F, Watanabe M, Kanno H, Aihara M, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Yamazaki F, Horii T, Maekawa M, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Iinuma Y, Maeda S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kinoshita S, Fujita J, Negayama K, Murase M, Miyamoto H, Kusano N, Mihara E, Itaha H, Ono J, Yoshimura H, Yanagihara K, Matsuda J, Saikawa T, and Hiramatsu K

Subjects
Drug Resistance, Bacterial, Gram-Negative Bacteria enzymology, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections microbiology, Gram-Positive Bacteria enzymology, Gram-Positive Bacteria isolation & purification, Gram-Positive Bacterial Infections microbiology, Humans, Injections, Intravenous, Japan, Meropenem, Time Factors, beta-Lactamases biosynthesis, Anti-Bacterial Agents pharmacology, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 876 strains of Gram-positive bacteria, 1764 strains of Gram-negative bacteria, and 198 strains of anaerobic bacteria obtained from 30 medical institutions during 2006 was measured. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, all of the MEPM-resistant strains were resistant to imipenem (IPM). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (41.8%) and ciprofloxacin-resistant P. aeruginosa (33.3%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 4.3% (6 strains) in Escherichia coli, 1.1% (1 strain) in Citrobacter freundii, 21.7% (5 strains) in Citrobacter koseri, 3.1% (4 strains) in Klebsiella pneumoniae, 3.3% (3 strains) in Enterobacter cloacae, 0.8% (1 strain) in Serratia marcescens, and 4.9% (2 strains) in Providencia spp. The proportion of metallo-beta-lactamase strains was 3.1% (10 strains) in P. aeruginosa. 4. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 11 years after available for commercial use.

Published
2007

3. [In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004].

Author

Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, Tsujio Y, Kimoto H, Kaimori M, Nakamura T, Kawamura C, Nishimura M, Akizawa K, Katayama Y, Matsuda K, Hayashi T, Yasujima M, Kasai T, Kimura M, Tominaga M, Miki M, Nakanowatari S, Nakagawa T, Kaku M, Kanemitsu K, Kunishima H, Toyoshima S, Sakurai M, Shiotani J, Sugita A, Ito T, Okada J, Suwabe A, Yamahata K, Yoneyama A, Kumasaka K, Yamane N, Koike K, Ieiri T, Kominami H, Yamada T, Oguri T, Itoh K, Watanabe K, Kobayashi Y, Ohtake T, Uchida T, Totsuka K, Murakami M, Yomoda S, Takahashi A, Okamoto H, Inuzuka K, Yamazaki K, Gonda H, Yamashita T, Yamaguchi I, Okada M, Ikari H, Kurosawa N, Fujimoto Y, Ishigo S, Asano Y, Mikio M, Kano I, Nagano E, Kageyama F, Shaku E, Kanno H, Aihara M, Gemma H, Uemura K, Miyajima E, Maesaki S, Hashikita G, Horii T, Sumitomo M, Yoshimura H, Hiraoka M, Wada H, Yuzuki Y, Ikeda N, Baba H, Soma M, Yamamoto T, Ichiyama S, Kinosita S, Kawano S, Fujita S, Kageoka T, Hongo T, Okabe H, Tatewaki K, Moro K, Oka M, Niki Y, Yoshida H, Yamashita M, Kusano N, Mihara E, Nose M, Fushiwaki T, Kuwabara M, Fujiue Y, Shimuzu A, Takubo T, Kusakabe T, Hinoda Y, Tanaka N, Takahashi H, Heijyou H, Okazaki T, Asai K, Kawahara K, Masuda J, Sano R, Taminato T, Negayama K, Matsuo S, Komatsu M, Sugiura T, Murase M, Hiramatsu K, Yamane N, Nakasone I, Hirakata Y, Kohno S, Aizawa H, Honda J, Hamazaki N, Okayama A, Ono J, Aoki Y, Okada K, and Miyanohara H

Subjects
Drug Resistance, Microbial, Fluoroquinolones pharmacology, Humans, Japan, Time Factors, Anti-Bacterial Agents pharmacology, Bacterial Infections microbiology, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Positive Cocci drug effects, Gram-Positive Cocci isolation & purification, Gram-Positive Rods drug effects, Gram-Positive Rods isolation & purification
Abstract

A total of 18,639 clinical isolates in 19 species collected from 77 centers during 2004 in Japan were tested for their susceptibility to fluoroquinolones (FQs) and other selected antibiotics. The common respiratory pathogens, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae showed a high susceptible rate against FQs. The isolation rate of beta lactamase non-producing ampicillin-resistant H. influenzae was approximately three times as large as those of western countries. Most strains of Enterobacteriaceae were also susceptible to FQs. The resistance rate of Escherichia coli against FQs has however been rapidly increasing so far as we surveyed since 1994. The FQs-resistant rate in methicillin-resistant Staphylococcus aureus (MRSA) showed approximately 90% except for 36%. of sitafloxacin while FQs-resistant rate in methicillin-susceptible S. aureus (MSSA) was around 5%. The FQs-resistant rate of methicillin-resistant coagulase negative Staphylococci (MRCNS) was also higher than that of methicillin-susceptible coagulase negative Staphylococci (MSCNS), however, it was lower than that of MRSA. In Pseudomonas aeruginosa clinical isolates, 32-34% from UTI and 15-19% of from RTI was resistant to FQs. Acinetobacter spp. showed a high susceptibility to FQs. Although FQs-resistant Neisseria gonorrhoeae have not been increased in western countries, it is remarkably high in Japan. In this survey, isolates of approximately 85% was resistant to FQs.

Published
2006

4. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].

Author

Yamaguchi K, Murakami M, Takahashi A, Ishii Y, Iwata M, Itoh K, Oohara T, Watanabe N, Uehara N, Nomura F, Watanabe M, Yasujima M, Kasai T, Kanno H, Aihara M, Suwabe A, Yamahata K, Maesaki S, Hashikita G, Kaku M, Kanemitsu K, Miyake K, Oguri T, Yoshida H, Nishiyama K, Okada J, Tazawa Y, Komatsu M, Nakashima H, Takemura H, Kinoshita S, Okada M, Kobayashi S, Taminato T, Negayama K, Horii T, Murase M, Miyamoto H, Baba H, Kusano N, Mihara E, Ishigo S, Kambe M, Itaha H, Fujita N, Komori T, Ono J, Yoshimura H, Ichiyama S, Maeda S, Hirakata Y, Matsuda J, Yamanaka K, Mutara Y, Saikawa T, Hiramatsu K, and Taminato S

Subjects
Anti-Infective Agents administration & dosage, Carbapenems pharmacology, Drug Resistance, Multiple, Bacterial, Injections, Intravenous, Meropenem, Thienamycins administration & dosage, Anti-Infective Agents pharmacology, Bacteria, Anaerobic drug effects, Drug Resistance, Bacterial, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-beta-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 microg/ml --> 1 microg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

Published
2005

5. [In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002].

Author

Yamaguchi K, Ohno A, Kashitani F, Iwata M, Kanda M, Tsujio Y, Shimoyama N, Okujima H, Ito M, Kawaguchi H, Chiba H, Akizawa K, Katayama Y, Sugimoto K, Tashiro H, Kaimori M, Suwabe A, Obata R, Sugiyama T, Toyoshima S, Kato J, Kaku M, Kanemitsu K, Kunishima H, Okada J, Tazawa Y, Igari J, Oguri T, Watanabe K, Kobayashi Y, Uchida H, Totsuka K, Kon S, Nakamura K, Matsuda K, Hayashi I, Shiotani J, Shiotani J, Kanno H, Itoh A, Sumitomo M, Uchida T, Kawabata A, Oiwa C, Iwata M, Horii T, Ishigo S, Yoshimura T, Ichiyama S, Wada Y, Kimura S, Maesaki S, Itoh K, Noda Y, Yamashita T, Yamaguchi I, Kageyama F, Shaku E, Baba H, Inuzuka K, Okabe H, Tatewaki K, Moro K, Aihara M, Matsushima T, Niki Y, Kuw Abara M, Ikawa S, Tanaka M, Hinoda Y, Sugiura T, Kamioka M, Ono J, Takata T, Makino H, Murase M, Miyamoto H, Aizawa H, Honda J, Takii M, Nagasawa Z, Aoki Y, Hamazaki N, Tsutsui T, Nakagawa K, Iwata M, Hiramatsu K, Saikawa T, Yamane N, Kimoto H, Kotani T, Kageoka T, Hongo T, Masuda J, Miyanohara H, Tsujimura M, Yasujima M, and Hayashi I

Subjects
Escherichia coli drug effects, Humans, Methicillin Resistance, Microbial Sensitivity Tests, Staphylococcus aureus drug effects, Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects, Levofloxacin, Ofloxacin pharmacology
Abstract

The susceptibilities of bacteria to fluoroquinolones (FQs), especially levofloxacin, and other antimicrobial agents were investigated using 11,475 clinical isolates collected in Japan during 2002. Methicillin susceptible staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, the family of Enterobactericeae, Haemophilus influenzae and Acinetobacter spp. exhibited stable and high susceptibilities to FQs. The rate of FQs-resistant MRSA was 80 approximately 90%, being markedly higher than that of FQs-resistant MSSA. The FQs-resistance rate of MRCNS was also higher than that of MSCNS, however, it was lower than that of MRSA. No FQs-resistant clinical isolates of Salmonella spp. were detected in any of the surveys. Thirteen of Escherichai coli 696 isolates, 8 of Klebsiella pneumoniae 630 isolates and 33 of Proteus mirabilis 373 isolates produced extended-spectrum beta-lactamase (ESBL), furthermore 6 of 13 in E. coli, 1 of 8 in K. pneumoniae and 14 of 31 ESBL-producing isolates, and in P. mirabilis were FQs resistant. Attention should be focused in the future on the emergence of ESBL in relation to FQs resistance. The rate of FQs-resistant P. aeruginosa isolated from urinary tract infection (UTI) was 40 approximately 60%, while 15 approximately 25% of isolates from respiratory tract infection (RTI) were resistant. IMP-1 type metallo beta-lactamase producing organisms were found in 49 of P. aeruginosa 1,095 isolates, 7 of S. marcescens 586 isolates and 4 of Acinetobacter spp. 474 isolates, respectively. Glycopeptide-resistant enterococci or S. aureus was not found.

Published
2005

6. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].

Author

Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, Kanda M, Tsujio Y, Okada J, Tazawa Y, Watanabe N, Uehara N, Igari J, Oguri T, Kaimori M, Kawamura C, Iinuma Y, Nisawataira T, Tashiro H, Ueno K, Ishigo S, Yasujima M, Kawahara S, Itoh C, Yoshida T, Yamanaka K, Toyoshima S, Katoh J, Kudoh M, Matsushima T, Niki Y, Miyashita N, Funato T, Kaku M, Sato N, Saito Y, Ishii K, Kuwabara M, Hongo T, Negayama K, Kamihira S, Miyazaki Y, Takii M, Ishii M, Nakagawa K, Ono J, Takada T, Murakami N, Taira M, Tamaki I, Matsudou Y, and Nakasone I

Subjects
Ciprofloxacin pharmacology, Drug Resistance, Microbial, Humans, Levofloxacin, Naphthyridines pharmacology, Ofloxacin pharmacology, Respiratory Tract Infections microbiology, Urinary Tract Infections microbiology, Anti-Infective Agents pharmacology, Fluoroquinolones, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects
Abstract

The surveillance study was conducted to determine the antimicrobial activity of fluoroquinolones (ofloxacin, levofloxacin, ciprofloxacin, tosufloxacin) and other 20 antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. The resistance to fluoroquinolones was remarkable in Enterococci, methicillin-resistant staphylococci and Pseudomonas aeruginosa from UTI. However, many of the common pathogens such as Streptococcus pneumoniae including penicillin-resistant isolates, methicillin-susceptible Stahylococcus aureus, Moraxella catarrhalis, the family of Enterobacteriaceae, Haemophilus influenzae including ampicillin-resistant isolates have been kept to be susceptible to fluoroquinolones. About 90% of P. aeruginosa isolates from RTI were susceptible to fluoroquinolones. In conclusion, the results from this surveillance study suggest that fluoroquinolones are useful in the treatment of various bacterial infections including respiratory infections.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results